News · 26 weeks66+100%
2026-04-192026-10-11
Mix2190d
- Other7(33%)
- Insider6(29%)
- SEC Filings5(24%)
- Earnings1(5%)
- Offering1(5%)
- Analyst1(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Celcuity Inc.4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERSEC Form 4 filed by Celcuity Inc.4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERSEC Form 3 filed by Celcuity Inc.3 - Celcuity Inc. (0001603454) (Issuer)
- PRCelcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA wild-type cohort of VIKTORIA-1 and other regimens evaluated in patients with HR+/HER2- advanced breast cancer Poster presentation of sub-group analyses from the Phase 1b trial of gedatolisib plus darolutamide in patients with mCRPC MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that a late breaking rapid ora
- SECCelcuity Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Celcuity Inc. (0001603454) (Filer)
- PRCelcuity Appoints David Gryska To Its Board Of DirectorsMINNEAPOLIS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced the appointment of David W. Gryska to its Board of Directors. Mr. Gryska is a seasoned executive who brings over 35 years of strategic and financial leadership experience in the life sciences industry to Celcuity, including advising early-stage biotechnology companies. "On the heels of our first FDA approval for REVTORPYK™, we are pleased to welcome David to our Board of Directors as we transition into a commercial-stage company," said Brian Sullivan, Chief Exe
- SECCelcuity Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Celcuity Inc. (0001603454) (Filer)
- PRCelcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United StatesREVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic settingREVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 to comprehensively blockade the PI3K/AKT/mTOR ("PAM") pathwayIn the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial, the REVTORPYK triplet and REVTORPYK doublet reduced the risk of disease progression or death by 76% and 67%, respectively, compared to fulvestrantHealthcare providers can visit www.revtorpykhcp.com to access a comprehensive p
- ANALYSTAnalyst initiated coverage on Celcuity with a new price targetAnalyst initiated coverage of Celcuity with a rating of Overweight and set a new price target of $157.00
- PRCelcuity To Participate in Upcoming Investor ConferencesMINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Wells Fargo 21st Annual Healthcare Conference at 10:15 a.m. EDT on Tuesday, September 8, 2026. A live webcast will be available using this weblink.A fireside chat at Citi's 2026 Biopharma Back to School Summit at 8:00 a.m. EDT on Wednesday, September 9, 2026. A live
- SECCelcuity Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Celcuity Inc. (0001603454) (Filer)
- PRCelcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast CancerIf approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application ("sNDA") to the U.S. Food and Drug Administration ("FDA") for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive ("HR+"), human epidermal growth factor receptor 2 negative ("HER2-"), locally a
- INSIDERChief Science Officer Laing Lance G. was granted 20,000 shares, increasing direct ownership by 2% to 1,271,000 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERChief Executive Officer Sullivan Brian F. was granted 80,000 shares, increasing direct ownership by 6% to 1,450,199 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERChief Financial Officer Hahne Vicky was granted 16,000 shares, increasing direct ownership by 73% to 37,808 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- SECSEC Form 10-Q filed by Celcuity Inc.10-Q - Celcuity Inc. (0001603454) (Filer)
- SECCelcuity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Celcuity Inc. (0001603454) (Filer)
- PRCelcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate UpdateREVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer on July 14, 2026; on track for commercial launch late third quarter 2026NCCN® Clinical Practice Guidelines recommended REVTORPYK in combination with fulvestrant, with or without palbociclib, as a preferred Category 1 option for second-line therapy in HR+/HER2- advanced breast cancerThe Phase 3 PIK3CA mutant cohort of the VIKTORIA-1 trial achieved its primary endpoint by doubling the likelihood of survival without disease progression or death compared to alpelisib plus fulvestrant; a supplemental New Drug Application ("sNDA") is planned for submission
- SECSEC Form SCHEDULE 13G filed by Celcuity Inc.SCHEDULE 13G - Celcuity Inc. (0001603454) (Subject)
- PRCelcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference CallMINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that it will release its financial results for the second quarter 2026 after the market closes on Thursday, August 13, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Daylight Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-18
- PRNewly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast CancerMINNEAPOLIS, July 30, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced that REVTORPYK™ (gedatolisib) in combination with fulvestrant, with or without palbociclib, is recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a preferred Category 1 second-line and/or subsequent-line therapy following progression on or after treatment with at least one line of endocrine therapy. REVTORPYK was granted approval by the U.S. Food and Drug Administration ("FDA") on July 14, 2026, for t
- SECSEC Form SCHEDULE 13G filed by Celcuity Inc.SCHEDULE 13G - Celcuity Inc. (0001603454) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Celcuity Inc.SCHEDULE 13D/A - Celcuity Inc. (0001603454) (Subject)
- INSIDERFormer 10% owner Baker Bros. Advisors Lp sold $317,750,000 worth of shares (3,100,000 units at $102.50) (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- SECAmendment: Celcuity Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K/A - Celcuity Inc. (0001603454) (Filer)
CELC FAQ
7 questionsWhat does Celcuity Inc. do?
Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis...Where does CELC stock trade?
Celcuity Inc. (CELC) is listed on NASDAQ.What sector and industry is CELC in?
Celcuity Inc. operates in the Health Care sector, Medical Specialities industry.When did Celcuity Inc. go public?
Celcuity Inc. (CELC) completed its IPO in 2017.What are analysts saying about CELC?
Celcuity Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight on 2026-09-17. Recent price targets cluster around $3000.00.What companies are similar to CELC?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare CELC side-by-side with any of them on Quantisnow.How can I track CELC on Quantisnow?
Quantisnow aggregates Celcuity Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CELC to receive live email and push alerts on every new disclosure.